• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

    11/5/25 8:35:00 AM ET
    $BLTE
    $COE
    $HCM
    $LOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Real Estate
    Get the next $BLTE alert in real time by email

    NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held November 4th are now available for online viewing.

    VIEW PRESENTATIONS HERE

    The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section.

    November 4th Company Presentations

    HUTCHMED (China) Limited(AIM: HCM, NASDAQ:HCM, and HKEX:13)
    First Pacific Company Ltd((HKEX: 142, OTC:FPAFY)
    Viomi Technology Co., Ltd(NASDAQ:VIOT)
    Epiroc AB((Nasdaq Stockholm: EPIA, OTC:EPOAY)
    Yiren Digital Ltd.(NYSE:YRD)
    Belite Bio, Inc (NASDAQ:BLTE)
    Deutsche Lufthansa AG((FRA: LHA, OTCQX:DLAKY)
    Lotus Technology Inc(NASDAQ:LOT)
    51Talk Online Education Group(NYSE:COE)
    Radiopharm Theranostics Ltd(NASDAQ:RADX, ASX: RAD))
    Repsol S.A((BME: REP, OTCQX:REPYY)
      

    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    johnv@otcmarkets.com



    Primary Logo

    Get the next $BLTE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLTE
    $COE
    $HCM
    $LOT

    CompanyDatePrice TargetRatingAnalyst
    Belite Bio Inc
    $BLTE
    1/26/2026$195.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/6/2026$191.00Overweight
    Morgan Stanley
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    Belite Bio Inc
    $BLTE
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    11/20/2025$105.00Neutral
    Mizuho
    HUTCHMED (China) Limited
    $HCM
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    Radiopharm Theranostics Limited
    $RADX
    3/12/2025$15.00Buy
    B. Riley Securities
    More analyst ratings

    $BLTE
    $COE
    $HCM
    $LOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chen Wan-Shan

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/2/26 4:15:12 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chuang Hao-Yuan

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/2/26 4:15:10 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mata Nathan L.

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/2/26 4:15:09 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lotus Technology Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Delivered 6,520 vehicles1 and achieved total revenue of $519 million in 2025.Service revenues increased 69% YoY in 2025, affirming the Company's technology edge and validating the commercialization of its intellectual property (IP).Gross margin improved to 9% in 2025 mainly due to the commencement of upgraded model deliveries globally and disciplined cost control.Operating loss narrowed by 65% YoY and 29% QoQ in the fourth quarter, with the full-year operating loss narrowed by 46% YoY, demonstrating the Company's commitment to operational efficiencies.Debut of Company's first PHEV model, named For Me (Eletre X in Europe), extending product roadmap and catering to evolving consumer demands ac

    4/10/26 6:00:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2026, taking place on April 17-22, 2026 in San Diego, California. Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate ("ATTC") will be presented. The payload of HMPL-A580 potently inhibited PI3K and PIKK family kinases, with IC50 ranging around 1 to 10 nM. Eurofins profiling across 418 kinases revealed the

    4/8/26 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

    SYDNEY, April 08, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 130mCi in the Phase 1 ‘HEAT' clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors1. The DSMC is a multidisciplinary committee that conducts detailed revie

    4/8/26 7:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    SEC Filings

    View All

    SEC Form 6-K filed by Lotus Technology Inc.

    6-K - Lotus Technology Inc. (0001962746) (Filer)

    4/10/26 6:05:16 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    SEC Form 144 filed by Belite Bio Inc

    144 - BELITE BIO, INC (0001889109) (Subject)

    4/9/26 12:17:43 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    4/9/26 6:19:32 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Belite Bio with a new price target

    BofA Securities initiated coverage of Belite Bio with a rating of Buy and set a new price target of $195.00

    1/26/26 10:01:23 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Belite Bio with a new price target

    Morgan Stanley initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $191.00

    1/6/26 8:54:10 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio upgraded by Mizuho with a new price target

    Mizuho upgraded Belite Bio from Neutral to Outperform and set a new price target of $194.00

    12/2/25 8:17:09 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Leadership Updates

    Live Leadership Updates

    View All

    LOTUS Appoints Piano Master Lang Lang as Friend of the Brand

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus Tech" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today updated that LOTUS announced world-renowned pianist Lang Lang as its Friend of the Brand, marking a new partnership built on a shared pursuit of precision, performance, and excellence. Recognized globally for his extraordinary technique and expressive artistry, Lang Lang has brought classical music to audiences across cultures and generations. His dedication to mastery through discipline and refinement closely mirrors LOTUS's engineering philosophy, where every detail is shaped to deliver pure driving performance.

    2/6/26 8:30:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    Viomi Technology Co., Ltd Appoints Malaysian Pop Star Shila Amzah as Brand Ambassador and Announces New AI Water Purifier Launch in Malaysia

    GUANGZHOU, China, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of renowned Malaysian singer Ms. Shila Amzah as its brand ambassador in Malaysia. Ms. Amzah will join Viomi for a product launch event in Malaysia on October 30, where the Company will unveil its new AI water purifier, INNO, designed to bring a smarter and safer drinking water lifestyle to local households. Mr. Xiaoping Chen, Founder and CEO of Viomi, commented: "We are thrilled to welcome Ms. Shila Amzah as our brand ambassador in Malaysia. Together, at our upcoming product

    10/20/25 9:00:28 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

    SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

    12/17/24 4:07:04 PM ET
    $COE
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

    SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

    11/12/24 6:35:53 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/12/24 6:07:58 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    $BLTE
    $COE
    $HCM
    $LOT
    Financials

    Live finance-specific insights

    View All

    Lotus Technology Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Delivered 6,520 vehicles1 and achieved total revenue of $519 million in 2025.Service revenues increased 69% YoY in 2025, affirming the Company's technology edge and validating the commercialization of its intellectual property (IP).Gross margin improved to 9% in 2025 mainly due to the commencement of upgraded model deliveries globally and disciplined cost control.Operating loss narrowed by 65% YoY and 29% QoQ in the fourth quarter, with the full-year operating loss narrowed by 46% YoY, demonstrating the Company's commitment to operational efficiencies.Debut of Company's first PHEV model, named For Me (Eletre X in Europe), extending product roadmap and catering to evolving consumer demands ac

    4/10/26 6:00:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    Lotus Technology to Report Unaudited Q4 and Full Year 2025 Financial Results on Friday, April 10

    NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. (NASDAQ:LOT) ("Lotus Tech" or the "Company"), a leading global intelligent and luxury mobility provider, today announced that it will report its unaudited financial results for the fourth quarter and full year 2025 financial results on Friday, April 10, 2026, before market opening in the United States. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on Friday, April 10, 2026 (14:00 Central European Time / 20:00 China Standard Time on the same day). There will be a live audio webcast and limited-time replay available on the Company's investor relations website at https://ir.group

    4/1/26 7:55:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    51Talk Online Education Group Announces the Results for the Fourth Quarter and Full Year 2025

    SINGAPORE, March 27, 2026 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the fourth quarter and full year ended December 31, 2025. Full Year 2025 Financial and Operating HighlightsGross billings[1] for 2025 were US$127.6 million, an 83.4% growth from US$69.6 million for 2024.Net revenues were US$95.6 million for 2025, an 88.6% increase from US$50.7 million for 2024.The number of active students with attended lesson consumption was approximately 170,300 in 2025, representing a 79.3% increase from approximately 95,000 for 2024.Operati

    3/27/26 7:35:00 AM ET
    $COE
    Other Consumer Services
    Real Estate